Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity
Journal of Controlled Release · 2026
DOI: 10.1016/j.jconrel.2026.115136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Dao Thi Hong Le und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Si…. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanoparticles, Polycarboxylate Cement, RNA, Messenger. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A*STAR Research Entities, National Research Foundation, Biomedical Research Council.
Abstract (Originalsprache)
mRNA vaccines delivered by lipid nanoparticles (LNPs) have enabled clinical success in combating the COVID-19 pandemic, demonstrating LNPs as a promising nanocarrier for mRNA delivery. Despite this advance, use of PEGylated lipid (PEG-lipid) in LNPs has raised concerns about PEG-associated immunogenicity upon repeated dosing. Recent studies reported hydrophilic polymer lipids as replacement of PEG-lipid, which demonstrated the potential to reduce PEG-associated immune recognition. Most of these PEG-lipid alternatives are based on polymers with non-degradable polymer backbone. In this study, we synthesized a series of oligo(ethylene glycol)-functionalized polycarbonate lipids (OPL-1 to OPL-8) based on a polycarbonate backbone with reported biodegradability and biocompatibility to replace PEG-lipid such as ALC-0159 used in Comirnaty mRNA vaccine for attenuating PEG immunogenicity. Unlike ALC-0159 with 50 EG units existing in a linear form, oligo(ethylene glycol) (OEG) in OPLs is in a brush-like conformation. OEG length played a key role in formulating LNPs with desirable physicochemical properties. OPL-7 and OPL-8 with EG9 produced LNPs with nanosize, narrow size distribution, near-neutral surface charge and high encapsulation efficiency, comparable to ALC-0159 LNPs. OPL LNPs mediated significantly higher mRNA transfection efficiency in HEK293T and two model antigen-presenting cells (APCs) than ALC-0159 LNPs, which was associated with enhanced cellular uptake as evidenced by flow cytometry analysis. Endocytosis inhibition assay suggested that clathrin-mediated endocytosis was a major pathway for cellular uptake of LNPs, with caveolae-dependent endocytosis also contributing. A confocal microscopic study indicated comparable endosomal escape of OPL and ALC-0159 LNPs. In vivo and ex vivo bioimaging at 6 h post-administration demonstrated that OPL-7 and OPL-8 LNPs exhibited significantly reduced hepatic mRNA transfection and relatively higher lymph node mRNA transfection, resulting in significantly greater lymph node-to-liver mRNA transfection ratios. In a mouse vaccination study, OPL-7 and OPL-8 LNPs loaded with mRNA encoding the spike glycoprotein of SARS-CoV-2 Delta variant elicited robust humoral immune responses without causing significant toxicity. Repeated dosing of OPL-7 or OPL-8 LNPs induced significantly lower anti-PEG IgM response than ALC-0159 LNPs. Moreover, OPL-7 or OPL-8 avoided recognition by pre-existing anti-PEG antibodies. Collectively, these findings identify OPL-7 and OPL-8 as promising PEG-lipid alternatives for mRNA delivery that maintain delivery performance while attenuating anti-PEG antibody responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Singapore; Department of Orthopaedic Surgery, Yong Loo Lin School of Med…
- Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Singapore.
- Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore 119288, Singapore.
Förderung
- A*STAR Research Entities
- National Research Foundation
- Biomedical Research Council
Zitieren
APA
Le, D. T. H., Yang, C., Zhang, Y., Zhao, G., Seow, B. Y. L., Zhao, X., Balakrishnan, N., Bae, K. H., Hui, J. H. P., & Yang, Y. Y. (2026). Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115136
Vancouver
Le DTH, Yang C, Zhang Y, Zhao G, Seow BYL, Zhao X, et al. Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115136
BibTeX
@article{Le2026,
author = {Le, Dao Thi Hong and Yang, Chuan and Zhang, Yue and Zhao, Gui and Seow, Brandon Yi Loong and Zhao, Xinxin and Balakrishnan, Nithiyaa and Bae, Ki Hyun and Hui, James H P and Yang, Yi Yan},
title = {Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity},
journal = {Journal of Controlled Release},
year = {2026},
doi = {10.1016/j.jconrel.2026.115136}
}
EUVIMED